


**Patent Claims**

1. A compound of formula I

5



10 in which

R is -OH, -OA, phenoxy, Ar, -O-CO-A, SO<sub>3</sub>H, SO<sub>3</sub>A, -OSO<sub>3</sub>H, -OSO<sub>3</sub>A, -OSO<sub>2</sub>A, SO<sub>2</sub>A, Hal, COOH, COOA, CONH<sub>2</sub>, NHSO<sub>2</sub>A, COA, CHO or SO<sub>2</sub>NH<sub>2</sub>, or

15 two radicals R together are methylenedioxy or ethylenedioxy,

X is OH, or

two radicals X together are methylenedioxy or ethylenedioxy,

Ar is phenyl which is unsubstituted or monosubstituted, disubstituted or trisubstituted by A,

20 A is an unbranched or branched alkyl having 1-10 carbon atoms, in which 1-7 H atoms are optionally replaced by F,

Hal is F, Cl, Br or I,

n is 1, 2, 3 or 4, and

25 m is 1, 2, 3, 4 or 5, or

a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

30 2. A compound according to Claim 1,

in which

R is -OH or -OA, and

X is OH, or

35 a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

5 3. A compound according to Claim 1,  
in which

10 R is -OH or -OA,  
X is OH,  
A is an unbranched or branched alkyl having 1-6 carbon atoms,  
n is 1 or 2, and  
m is 1, 2 or 3, or  
a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

15 4. A compound according to Claim 1,  
in which

20 R is -OH or -OA, or  
two radicals R together are methylenedioxy or ethylenedioxy,  
X is OH,  
A is an unbranched or branched alkyl having 1-6 carbon atoms,  
n is 1 or 2, and  
m is 1, 2 or 3, or  
25 a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.


30 5. A compound according to Claim 1 selected from  
5-hydroxy-2-(2',4'-dihydroxybenzoyl)chromone,  
5-hydroxy-2-(2'-hydroxy-4',5'-methylenedioxybenzoyl)chromone,  
6-hydroxy-2-(2'-hydroxy-4',5'-methylenedioxybenzoyl)chromone, or  
6,7-methylenedioxy-2-(2'-hydroxy-4',5'-methylenedioxybenzoyl)-chromone, or  
35 a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

6. A process for preparing a compound according to Claim 1 or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof comprising

5

a) reacting a compound of formula II

10




in which

15

X and n are as defined in Claim 1,  
with a compound of formula III


20



25

in which A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,  
to give a compound of formula IV

30




35

in which X and n are as defined in Claim 1, and A is alkyl having 1, 2,  
3, 4, 5 or 6 carbon atoms,

b) then hydrolysing the compound of formula IV to a compound of formula V

5




10

in which X and n are as defined in Claim 1,

c) then converting the compound of formula V to a compound of formula VI

15




20

in which X and n are as defined in Claim 1,

and then reacting the compound of formula VI with a compound of formula VII

25



in which R and m are as defined in Claim 1,

in a Friedel-Crafts acylation to give a compound of the formula I,

30

and/or

d) a compound of formula I is converted into a salt or into a solvate and/or a stereoisomer of a compound of formula I is isolated.

35

7. A pharmaceutical composition comprising a compound according to Claim 1 or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof and one or more pharmaceutically acceptable excipients and/or adjuvants.  
5
8. A method of inhibiting tyrosine kinase comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.  
10
9. A method of treating a solid tumor in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.  
15
10. A method according to Claim 9, wherein the solid tumor is a cerebral tumor, a tumor of the genito-urinary tract, a tumor of the lymphatic system, a stomach tumor, a laryngeal tumor or a lung tumor.  
20
11. A method according to Claim 9, wherein the solid tumor is monocytic leukaemia, lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma or breast carcinoma.  
25
12. A method of treating a disease by inhibiting angiogenesis in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.  
30
13. A method according to Claim 12, wherein the disease is an ocular disease.  
35
14. A method of treating retinal vascularisation in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

15. A method of treating diabetic retinopathy in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 5 16. A method of treating an age-related macular degeneration in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 10 17. A method of treating an inflammatory disease in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 15 18. A method according to claim 17, wherein the inflammatory disease is rheumatoid arthritis, psoriasis, contact dermatitis or a delayed hypersensitivity reaction.
- 20 19. A method of treating a tyrosine kinase-dependent disease or a tyrosine kinase-dependent condition in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 25 20. A method of treating a bone pathology comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 30 21. A method according to claim 20, wherein the bone pathology is osteosarcoma, osteoarthritis or rickets.
22. A pharmaceutical composition according to claim 7, further comprising an additional pharmaceutically active compound.
- 35 23. A kit comprising separate packs of

(a) a pharmaceutical composition according to Claim 7 or a compound of formula I or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof,  
and  
5 (b) an additional pharmaceutically active compound or composition.

24. A method according to claim 9, further comprising administering an oestrogen receptor modulator, an androgen receptor modulator, a retinoid receptor modulator, a cytotoxic agent, an antiproliferative  
10 agent, a prenyl-protein transferase inhibitor, an HMG-CoA reductase inhibitor, an HIV protease inhibitor, a reverse transcriptase inhibitor or an angiogenesis inhibitor.

15 25. A method according to claim 24, further comprising performing radiotherapy on said mammal.

20 26. A method of treating a disease related to an oxidative stress condition in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

25 27. A method according to claim 25, wherein the disease is memory loss or a neurodegenerative disorder.

30 28. A food supplement comprising a compound of claim 1.

29. A cosmetic composition comprising a compound of claim 1.

35 30. A method of protecting the proteins of the skin from stress comprising applying a cosmetic composition of claim 29 to the skin.


31. A topically applicable cosmetic composition comprising a compound of claim 1.

32. A cosmetic composition according to claim 29, containing 0.0001 to 50% by weight of a compound of claim 1.

33. A compound of formula VI

5

10



VI

in which

X is OH, or

15 two radicals X together are methylenedioxy or ethylenedioxy, and

n is 1, 2, 3 or 4, or a

salt thereof.

20

25

30

35